The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation

Documenti analoghi

• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
  di: Wu, Shang-Gin, et al.
  Pubblicazione: (2016)
• Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations
  di: Chen, Yi-Chieh, et al.
  Pubblicazione: (2021)
• The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations
  di: Yang, Chih-Jen, et al.
  Pubblicazione: (2017)
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
  di: Gow, Chien-Hung, et al.
  Pubblicazione: (2005)
• Mutation Variants and Co‐Mutations as Genomic Modifiers of Response to Afatinib in HER2‐Mutant Lung Adenocarcinoma
  di: Fang, Wenfeng, et al.
  Pubblicazione: (2019)